Trial Profile
A limited access phase II trial of cetuximab (C225, NSC 714692) in combination with cisplatin (NSC 119875) in the treatment of advanced, persistent, or recurrent carcinoma of the cervix
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Cisplatin
- Indications Cervical cancer
- Focus Adverse reactions; Therapeutic Use
- 05 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Mar 2008 Status changed from recruiting to in progress.
- 27 Dec 2007 The expected completion date for this trial is now 1 Sep 2008.